文献速递腹部介入MR

TACE后ADC直方图变化预测边界清晰肝细胞癌患者的总生存期和无移植生存期:一项随访长达10年的回顾性队列研究

Post-TACE changes in ADC histogram predict overall and transplant-free survival in patients with well-defined HCC: a retrospective cohort with up to 10 years follow-up.
PubMed 文献 · Eur Radiol · 2020-09-07

该回顾性队列纳入104例边界清晰的肝细胞癌患者,分析首次传统TACE前后肝脏MRI的ADC直方图变化,发现ADC均值增幅(ΔADC)是更长总生存期和无移植生存期的独立预测因子,ΔADC≥35%者生存最佳;在ΔADC<35%的非应答者中,ADC峰度变化(ΔkADC)可区分生存预后,ΔkADC≥1者生存最差。

要点

  • TACE后ADC均值增幅≥35%提示生存预后良好,且为独立预测因子。
  • ADC增幅<35%者中,ADC峰度变化≥1提示肿瘤趋于均匀、生存最差。
  • ADC增幅<35%且峰度变化<1者提示部分应答、生存尚可。

核心结论

  • ADC均值和ADC峰度的变化作为组织异质性变化的指标,可用于预测边界清晰肝细胞癌患者的总生存期和无移植生存期。
  • 上述变化有助于监测TACE早期应答,识别治疗失败和生存预后差的患者。

研究设计与样本

  • 回顾性队列研究,检索2005—2016年机构数据库中接受传统TACE的肝细胞癌患者。
  • 纳入104例边界清晰且具有完整TACE前后肝脏MRI的患者,共分析367人年随访数据。
  • 测量肿瘤体积、ADC均值、ADC直方图偏度和峰度等容积MRI指标,采用单因素和多因素Cox模型检验影像参数变化的独立预测作用,P<0.05为显著。

诊断标准与关键数值

  • 应答组定义为ΔADC≥35%,非应答组定义为ΔADC<35%,应答组较非应答组生存预后最佳(p<0.001)。
  • 在非应答者中,ΔkADC可区分生存差与尚可(p<0.001),但在应答者中不能区分(p=0.244)。
  • 以应答组为参照,非应答且ΔkADC≥1者生存最差(HR=5.70,p<0.001),非应答且ΔkADC<1者生存尚可(HR=2.51,p=0.029)。
  • 校正基线肝功能、肿瘤体积和治疗方式后,ΔADC是更长总生存期和无移植生存期的独立预测因子(p=0.009)。
  • ADC峰度下降(ΔkADC)对预测更长生存期显示出强作用(p=0.021)。

临床应用与阅片要点

  • 作者认为,ADC均值和ADC峰度的变化可用于预测边界清晰肝细胞癌患者的总生存期和无移植生存期,以监测TACE早期应答并识别治疗失败和生存预后差的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the role of change in apparent diffusion coefficient (ADC) histogram after the first transarterial chemoembolization (TACE) in predicting overall and transplant-free survival in well-circumscribed hepatocellular carcinoma (HCC).

METHODS: Institution database was searched for HCC patients who got conventional TACE during 2005-2016. One hundred four patients with well-circumscribed HCC and complete pre- and post-TACE liver MRI were included. Volumetric MRI metrics including tumor volume, mean ADC, skewness, and kurtosis of ADC histograms were measured. Univariate and multivariable Cox models were used to test the independent role of change in imaging parameters to predict survival. P values < 0.05 were considered significant.

RESULTS: In total, 367 person-years follow-up data were analyzed. After adjusting for baseline liver function, tumor volume, and treatment modality, incremental percent change in ADC (ΔADC) was an independent predictor of longer overall and transplant-free survival (p = 0.009). Overall, a decrease in ADC-kurtosis (ΔkADC) showed a strong role in predicting longer survival (p = 0.021). Patients in the responder group (ΔADC ≥ 35%) had the best survival profile, compared with non-responders (ΔADC < 35%) (p < 0.001). ΔkADC, as an indicator of change in tissue homogeneity, could distinguish between poor and fair survival in non-responders (p < 0.001). It was not a measure of difference among responders (p = 0.244). Non-responders with ΔkADC ≥ 1 (homogeneous post-TACE tumor) had the worst survival outcome (HR = 5.70, p < 0.001), and non-responders with ΔkADC < 1 had a fair survival outcome (HR = 2.51, p = 0.029), compared with responders.

CONCLUSIONS: Changes in mean ADC and ADC kurtosis, as a measure of change in tissue heterogeneity, can be used to predict overall and transplant-free survival in well-circumscribed HCC, in order to monitor early response to TACE and identify patients with treatment failure and poor survival outcome.

KEY POINTS: • Changes in the mean and kurtosis of ADC histograms, as the measures of change in tissue heterogeneity, can be used to predict overall and transplant-free survival in patients with well-defined HCC. • A ≥ 35% increase in volumetric ADC after TACE is an independent predictor of good survival, regardless of the change in ADC histogram kurtosis. • In patients with < 35% ADC change, a decrease in ADC histogram kurtosis indicates partial response and fair survival, while ∆kurtosis ≥ 1 correlates with the worst survival outcome.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Shaghaghi M, Aliyari Ghasabeh M, Ameli S, et al. Post-TACE changes in ADC histogram predict overall and transplant-free survival in patients with well-defined HCC: a retrospective cohort with up to 10 years follow-up. Eur Radiol. 2020. PMID: 32894356. doi:10.1007/s00330-020-07237-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。